Saturday 17 October 2026
Export IDYA’s income statement to Excel — free account
IDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024. In the quarter to June 2026, revenue grew 125.8%, EPS fell 38.6% and free cash flow fell 41.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
32.85
1.00
−2.95%
Follow IDYA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (16.22%) | (14.28%) | (10.92%) | (14.15%) |
+8 more TTM periods Free account |
|
| (14.89%) | (13.14%) | (10.18%) | (13.26%) | ||
ROIC |
(36.65%) | (43.10%) | (25.96%) | (44.22%) | |
Return on Tangible Assets |
(22.16%) | (21.89%) | (18.45%) | (21.54%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.24) | (0.99) | (0.83) | (1.19) | |
Free Cash Flow |
(113.87) | (87.93) | (73.47) | (105.39) | |
Capital Expenditures |
(2.21) | (2.00) | (2.37) | (3.14) | |
| Other line items | |||||
Cash ROIC |
(5.62%) | (5.47%) | (4.42%) | (5.61%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
159.75% | 148.15% | 136.43% | 164.90% | |
Selling, General and Administrative Expense of Revenue |
32.92% | 30.19% | 27.45% | 24.82% | |
Share Based Compensation of Revenue |
23.58% | 22.00% | 19.99% | 19.61% | |
Operating CF/Net income |
0.64 | 0.61 | 0.63 | 0.64 | |
Depreciation/Fixed assets |
(0.15) | (0.32) | (0.66) | (1.14) | |
Capex/Depreciation |
1.77 | 0.71 | 0.44 | 0.34 | |
Revenue per Share |
2.54 | 2.58 | 2.61 | 2.52 | |
Operating CF per Share |
(1.21) | (0.97) | (0.80) | (1.16) | |
Capex per Share |
(0.02) | (0.02) | (0.03) | (0.04) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates